Vinge advises EQT Healthcare Growth, a new dedicated healthcare buy-out strategy introduced by EQT, in connection with its first investment – the acquisition of the biotech company, Mabtech, from IK Small Cap II Fund and several minority sellers.

EQT Healthcare Growth is a new buy-out strategy that builds on EQT’s 30-year healthcare track record, focused on scaling innovative, fast-growing healthcare companies to help deliver positive outcomes across the value chain. By helping companies build commercial muscle and expand their global reach, the strategy aims to enable the development of medical research, diagnostics, tools and treatments to deliver more efficient and accessible healthcare.

Mabtech is a category leading provider of tests and kits for studying immune responses predominantly in vaccine, infectious diseases, and oncology research. The company is based in Sweden and has over 900 customers in more than 60 countries. EQT Healthcare Growth will support Mabtech as it looks to expand its scale and reach.

The transaction is subject to customary conditions and approvals and is expected to close in Q1 2024.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson, Robin Sultani and Filip Magnusson (M&A), Stojan Arnerstål and Rebecka Målquist (IPR), Louise Brorsson Salomon, Helena Göransson, Kamyar Najmi and August Ahlin (Financing), Christoffer Nordin and Rebecka Danelius Gedin (Agreements and Permits), Mika Jordan and Elis Allmark (IT), Nicklas Thorgerzon and Lisa Hörnqvist (GDPR), Gulestan Ali (Employment), Kristoffer Larson (Real Estate), Mia Falk, Sam Fakhraie Ardekani and Maja Höglund (Compliance and Sanctions), Sebastian Örndahl, Daniel Wendelsson, Dagne Sabockis, Lovisa Lewin and Hilda Ivarson (Regulatory) and Gabriella Balbo (Transaction Support Coordinator).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025